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Abstract Benign hereditary chorea (BHC) is an auto-
somaldominant disorder of early onset characterized by a
slowly progressing or nonprogressing chorea, without cog-
nitive decline or other progressive neurologic dysfunction,
but also by the existence of heterogeneity of the clinical
presentation within and among families. The genetic cause
of BHC is the presence of either point mutations or dele-
tions in the thyroid transcription factor 1 gene (TITF1). We
studied a Portuguese BHC family composed of two pro-
bands: a mother and her only son. The patients were iden-
tified in a neurology out-patient clinic showing mainly
involuntary choreiformmovements since childhood, myoc-
lonic jerks, falls, and dysarthria. We performed magnetic
resonance imaging (MRI), electroencephalogram (EEG),
nerve conduction studies, thyroid ultrasound scan, bio-
chemical thyroid tests, and electrocardiogram (ECG). We
excluded Huntington disease by appropriate genetic testing
and sequenced the entire TITF1 gene for both patients. The
patients showed MRI alterations: (1) in the mother, ab-
normal hyperintense pallida and cortical cerebral/cerebellar
atrophy; and (2) in the son, small hyperintense foci in the
cerebellum and subtle enlargement of the fourth ventricle.
Sequence analysis of the TITF1 gene in these patients re-
vealed the presence of a heterozygous C > T substitution at
nucleotide 745, leading to the replacement of a glutamine
at position 249 for a premature stop codon. A previously
undescribed nonsense mutation in the TITF1 gene was
identified as being the genetic cause of BHC in this family.
Keywords Choreoathetosis . Nkx2.1 . Thyroid
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Introduction
Benign hereditary chorea (BHC), first described in 1967
[1], is a dominantly inherited disorder of early onset that is
characterized by a very slowly progressing or nonprogres-
sing chorea without cognitive decline or other progressive
neurologic dysfunction. This is in contrast with the demen-
tia and progressive course of chorea, which are the hall-
marks of classical Huntington disease, another inherited
movement disorder. Heterogeneity of clinical presentation
exists within and among BHC families. Besides chorea,
many of the published cases of BHC include atypical clini-
cal features such as dystonia, myoclonic jerks, mild dys-
arthria or gait disturbances, and low-average intelligence
[2].
Until recently, doubts existed concerning the definition
of BHC as a separate and well-defined clinical entity [2].
However, the mapping and cloning of its causative gene on
chromosome 14q [3], the gene encoding thyroid transcrip-
tion factor 1 (TITF1), also known as NKX2-1, was even-
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tually reported in 2002 [4]. TITF1 is a member of the NK2
family homeodomain-containing transcription factors [5, 6].
In adult human tissues, TITF1 is exclusively expressed in
the thyroid and in the lung [7]. However, during human
development, the gene is expressed: (1) strongly in the ven-
tral diencephalon (hypothalamic area and infundibulum)
and in the telencephalon, more precisely, in the developing
basal ganglia region (striatum and paleostriatum); (2) in the
lung bud, firstly in the primary bronchi epithelia and at 9
weeks of gestation in the alveolar primordial epithelium; and
(3) weakly in the thyroid primordium [8]. Mutations in this
gene have been found in five independent BHC families of
Dutch, North American,Welsh, Italian, and Canadian origin
[4, 9–12], as well as in patients with a combination of cho-
reoathetosis, hypothyroidism, and pulmonary symptoms of
different origins [7, 13–18] (see Table 1 for review).
Moreover, evidence exists for the existence of genetic
heterogeneity within BHC cases [9]. We have investigated
the genetic basis of disease in a Portuguese family with
BHC and identified a previously undescribed point muta-
tion in the TITF1 gene.
Subjects and methods
Family Two patients (a mother and her only son, see
Fig. 1a) were referred to the neurology out-patient’s clinic
because of “tremor.” Clinical information was provided by
both probands, who denied the existence of other affected
family members beside themselves. Except for the pro-
band’s father, other relatives were unavailable for exam-
ination or genetic testing.
Patient 1 H.P. is a 30-year-old male. Involuntary move-
ments were first noted by his mother at the age of 10
months. He first walked at the age of 2 years and had
Table 1 Mutations in the TITF1 gene and their implications at the protein and phenotypic level
Reference
number
DNA sequence Consequence at
protein level
Protein domain
localization
Mode of
transmission
Phenotype
Thyroid
dysfunction
Pulmonary
alterations
Choreoathetosis
17 Deletion, including the entire
TITF1 gene and the PAX9 gene
Absence of
protein
E AD CH Severe Severe
15 Deletion of chromosome 14q12-
13.3, including the PAX9 gene
Absence of
protein
E de novo CH Severe Severe
4, 9 G713T W238L H AD CH NA Severe
4, 9 C727A R243S H AD NA NA Severe
(cerebellar
alterations,
dysarthria)
4, 12 ΔG908 G303fsX77 N AD NA NA Severe
4, 11 1.2-Mb deletion, including
the entire gene
Absence of
protein
E de novo NA NA Severe
13 255insG G86fsX322
(G115fsX322)
TN-H de novo CH Severe Severe
10 −2A>T splice acceptor site
of intron 2
I155fsX2 TN-H AD Absent Absent Severe
7 Deletion of chromosomal
region 14q11.2-q13.3,
including the entire gene
Absence of
protein
E NA CH Severe Severe
7 G2626T V235F H de novo CH Severe Severe
7 2595insGG L224fsX3 H de novo Mild Mild Severe
7 C2519A S199X H NA CH Absent Severe
7 C1302A C117X TN-H NA CH Severe Muscular
hypotonia
16 −2A>G splice acceptor site of
intron 2
I155fsX2 TN-H AD CH Severe Severe
14 859–860insC −Q287fsX121
(−Q317fsX121)
C de novo CH Severe Severe
18 G523T E175X (E205X) H AD CH Severe Severe
Current
study
C745T Q249X H AD Absent Absent Mild/severe
E Entire protein, AD autosomal dominant, CH congenital hypothyroidism, H homeodomain, NA information not available, N NK2-specific
domain, TN-H sequence between the TN and the homeodomain, C carboxyl terminal (after the NK2-specific domain)
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frequent falls throughout childhood, which ceased around
puberty. He said his first words at 18 months and has been
a stutterer since then. Learning difficulties were noticed,
and the patient was unable to complete high school. To the
best of our knowledge, these learning difficulties were not
assessed by cognitive measures at the time, although the
patient was referred to a psychologist and followed for
over a year after failing his fourth year at school twice (last
year of primary school). He then went on to complete
another four years at school, after which he quit and took
an electrician’s course by correspondence. There was no
history of respiratory insufficiency. Congenital strabismus
had been surgically corrected in childhood. The patient
worked as an air-conditioning technician; his jerks did not
interfere significantly with his professional performance.
The general examination of this patient was unremark-
able (height 176 cm, weight 72 kg). He had a stuttering
speech, which appeared explosive at times. Cranial nerve
examination was normal, except for a left upper lid ptosis
(postsurgical), without diplopia. There was mild spasticity
of the lower limbs, bilateral pes cavus, and a bilateral
hammer deformity of the first toe. He had quite subtle
involuntary movements, which were choreiform in upper
limbs and trunk. There was no tremor. The remainder of the
neurological examination was normal.
Patient 2 G.P. is a 59-year-old female. Information on the
mother’s past medical history was scarce. She walked at
the age of 2 years. She remembered having had “ticks” all
her life and insisted that they had been much worse than at
present. She occasionally lost her balance and had a few
major falls, one of which caused a luxation of her left
elbow. There were no respiratory complaints. She had at-
tended school only for 2 years and remembered having
problems with learning. The patient was of low stature and
obese (height 145 cm, weight 73.4 kg). She displayed
inappropriate laughter, and her speech was sometimes of
an explosive nature. Deep tendon reflexes were abolished.
There was a symmetrical hypesthesia for pain distally in
the lower limbs. Choreiform movements were striking and
affected the whole body. In spite of her occasional loss of
balance, she did not display a wide-based gait. There was
no tremor or any other neurological abnormalities.
Proband’s father The neurologic examination was normal
except for the presence of bilateral pes cavus and bilateral
hammer of the first toe.
Additional investigations We performed brain magnetic
resonance imaging (MRI) studies of both patients as well as
electroencephalogram (EEG), nerve conduction studies, a
Fig. 1 Brain magnetic reso-
nance imaging of patient 1 (a, b)
and patient 2 (c, d). Axial-T2-
weighted images of patient 1
show multiple small hyperin-
tense foci (arrows) in the supe-
rior vermis, both within the
cortex and in the subependymal
region (a), and no abnormalities
in the basal ganglia (b). Axial
(c) and coronal (d) T2-weighted
images of patient 2 show bilat-
eral and symmetrical foci of
hypersignal in the basal ganglia
involving the globus pallidus
(arrows) as well as moderate
cerebral cortical atrophy
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thyroid ultrasound scan, biochemical thyroid function tests
[free T3, T4, and thyroid-stimulating hormone (TSH)], and
electrocardiogram (ECG). Huntington disease was ex-
cluded by appropriate genetic testing [19].
Control population We have extracted DNA from 1,000
anonymous Guthrie cards obtained from the national neo-
natal phenylketonuria (PKU) screening program using the
Chelex method. The samples were randomly selected and
Fig. 2 The C745>T745 mutation
in the TITF1 gene results in a
substitution at codon 249 of a
glutamine for a stop codon
(Q249X ). a DNA (sequencing
chromatogram) and amino acid
sequences of a normal indivi-
dual (left) and of patient 1
(right). b Sequence alignment of
human TITF1 with homologs of
others species using Clustal W
(asterisk indicates identical or
conserved residues in all se-
quences, point indicates semi-
conserved substitutions, and
colon indicates conserved sub-
stitutions. The TN-, homeodo-
main and NK2-specific
domains are represented as
boxes relined with dots,
solid lines, and dashes, respec-
tively. The red asterisk indicates
the nonsense mutation present in
the Portuguese BHC family, and
the black arrows show all the
point missense, nonsense, and
frameshift mutations reported in
this protein. GenBank accession
numbers of protein sequence are
listed in “Subjects and methods”
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included two individuals from each district of Portugal
(n=100).
Genotype analysis After informed consent was obtained,
genomic DNAwas extracted from blood samples according
to standard protocols using the Puregene system (Gentra).
HD testing was performed, as described elsewhere by the
use of polymerase chain reaction (PCR) analysis, using
primers that flank the CAG repeat [19]. For mutation anal-
ysis of the TITF1 gene, genomic DNA was amplified by
PCR using primers flanking the exons of the gene as de-
scribed [4]. Sequence analysis was performed by cycle
sequencing using the same primers, and detection was per-
formed in anABI sequencer by a company (MWGBiotech).
Bioinformatic analysis All protein sequences were taken
from the TrEMBL database. The accession numbers of
human, dog, rat, mouse, zebrafish, and Xenopus laevis
TITF1 sequences are AAP88775, P43698, XP_216720,
P50220, NP_571664, and AAG17405, respectively. Mul-
tiple sequence alignment of TITF1 proteins was performed
using the Clustal W program [20].
Results
The brain MRI scan of the first patient, H.P., was un-
remarkable, except for subtle abnormalities of the cerebel-
lum, which were of undetermined significance: in the
vermis, both within the cortex and the subependymal re-
gion, multiple small hyperintense foci were seen (Fig. 1a).
There was no contrast enhancement of these lesions after
gadolinium injection. There was a small but definite en-
largement of the fourth ventricle. The mother, G.P., dis-
played symmetrical foci of hypersignal in T2 weighted
images, involving both globi pallida, as well as a moderate
cerebral cortical atrophy (Fig. 1c,d). There was also cortical
and subcortical cerebellar atrophy.
In both patients, EEG, nerve conduction studies, thyroid
function, and lung function tests were normal. A thyroid
ultrasound scan was also considered normal in both cases.
Regarding cognitive evaluation, patient 1 had a mini
mental examination of Folstein (MMSE) of 30/30 and a
low-normal intelligence (total WAIS−R=87). There was
cognitive impairment of patient 2 (MMSE 16/22, WAIS−
R=62, mentally retarded range).
No mutation was found in the HD gene, thus ruling out
Huntington disease. In both cases, (CAG)n sizes were 17
and 27 triplets corresponding to a normal allele and to a
normal class 2 allele of large size, respectively.
We have identified a heterozygous C > T substitution at
position 745 of the TITF1 gene in patients 1 and 2 (Fig. 2a).
This nucleotide replacement was not present in 100 con-
trols of Portuguese origin. The C745T mutation affects the
two known splice variants of this gene [21, 22], and orig-
inates the substitution of a conserved glutamine at position
249 of the protein by a premature stop codon. The Q249X
mutation is located at the very end of the helix III of the
homeodomain and gives rise to a protein lacking its 153
C-terminal amino acids, including the entire NK2-specific
domain (Fig. 2b).
Discussion
We have identified a new family with BHC of Portuguese
origin and provide additional confirmation that mutation of
TITF1 is a cause of this disorder in different populations.
The clinical presentation of the patients in this family
overlaps with that of the reported cases in the literature. The
variability of the neurological signs found in one or both of
our patients (e.g., spasticity, dysarthria, mental retardation,
and falls) is in accordance with the heterogeneity of the
published cases of BHC [2, 9]. Some of these features, such
as pes cavus and hammer toes, seen in patient 1, were shared
by the patient’s father, and are therefore most likely not due
to the TITF1 mutation.
Magnetic resonance imaging descriptions of patients
bearing TITF1 mutations are scant. In the published BHC
families with TITF1 mutations, MRI abnormalities were
either absent [4, 10], or unreported. In one of the more
severe cases of nonprogressive choreoathetosis, congenital
hypothyroidism and neonatal respiratory distress, asso-
ciated with TITF1 mutations, small, malformed pallida
were described, as well as cystic masses in the posterior part
of the sella turcica [7]. The observation of abnormal hyper-
intense pallida in patient 2 (the proband’s mother) is in
agreement with the fact that TITF1 is expressed in the
developing basal ganglia [8], and is consistent with the
malformed pallida reported by Krude et al. [7], as well as
with the absence of pallidal structures and basal forebrain
TrkA-positive neurons in Nkx2.1 knockout mice [23].
Since TITF1 is only expressed during human development
in the ventral forebrain [8], and no protein was detected in
adult human brain [7], TITF1 is probably important to
regulate the formation of basal ganglia, but not for their
function, once properly developed.
The cerebellar abnormalities found in the MRI scan of
patient 1, in the present report, have not, to our knowledge,
been described before, and their significance is unclear. The
DutchBHC family, carrying a R243Smutation in TITF1 [4],
presented cerebellar and pyramidal signs, but the patients’
MRIs revealed no alterations [3]. The cortical cerebral and
cortical/subcortical cerebellar atrophy seen in patient 2 can
possibly correlate with the observation thatNkx2.1 knockout
mice have reduced numbers of cortical migrating cells
expressing gamma-aminobutyric acid (GABA), DLX2,
and calbindin produced in the pallidum [23].
The mutation identified in this family was a nonsense
mutation at position 249 of TITF1, which was not present
in a sample of the general population, including 200 chro-
mosomes. The description of yet a novel mutation in
TITF1, together with the fact that approximately 46% of
the mutations reported in this gene were de novo mutations
[4, 7, 13–15], suggests that BHC results from multiple
mutational events worldwide.
The mechanism through which this nonsense mutation
may be leading to a dominant disease is unknown. Loss
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of function due to protein deletion or truncation, or to
mRNA nonsense-mediated decay, may be occurring, lead-
ing to haploinsufficiency, as has been proposed [7, 10, 13].
Alternatively, dominant-negative disruption of the TITF1-
containing transcriptional complexes may be the cause of
disease.
We propose that simple haploinsufficiency does not fully
explain the mechanism of disease in the spectrum of dis-
orders associated to TITF1 mutations, including BHC. The
phenotypic variability associated with TITF1 mutations
(Table 1) can be explained by the type, size, and/or local-
ization of the mutation, and consequently, by the affected
domain(s) of the protein in each case. Alterations of the
protein producing a gain or loss of a specific function,
associated to a certain domain, can be important for a
determined tissue or in a specific stage of development, but
not another.
The Q249X mutation gives rise to a protein containing
both the TH domain and the homeodomain, that only lacks
its last two amino acids of helix III, which are apparently
not fundamental for its normal function, at least in the rat
TITF1 and Drosophila melanogaster NK-2 homeodomain
homologs [24, 25]. Nevertheless, the mutant protein lacks
the 153 C-terminal amino acids, including the entire NK2-
specific domain. This domain serves as a protein–protein
interaction interface and is able to mask the transcriptional
activation of both the N-terminal and C-terminal activation
domains [26–28]; thus, it is probably important to regulate
the activation of specific genes by TITF1 during develop-
ment. Taking into account the phenotype of the two pa-
tients in this family, we propose that this mutant protein (if
translated) is able to bind to its target DNA-binding sites
and activate their transcription in the lung and thyroid
(through a functional homeodomain) but fails to activate
specific genes that are important for the embryonic devel-
opment of the basal ganglia (the only stage in which TITF1
is expressed in the central nervous system) because it lacks
the C-terminal domain.
However, at this time, there is not enough data available
to support the aforementioned hypothesis since many of
the reported cases have not been fully examined for the
whole phenotypic spectrum of BHC. Additionally, since
similar mutations, or even the same mutation, in TITF1
cause different phenotypes (corresponding to several com-
binations of choreoathetosis, hypothyroidism, and respira-
tory alterations), other factors such as environmental
exposure, hormonal and/or modifier genes can be contrib-
uting to this clinical variability.
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